Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M--Revenue $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M--EPS $--Operating Margin %--Piotroski F-Score--
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M--ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with IXJ

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
IXJKen Fisher 2015-12-31 Add0.02%$99.78 - $105.97
($102.96)
$ 92.28-10%Add 380.03%92,228
IXJKen Fisher 2015-09-30 Add$96.45 - $113.73
($107.78)
$ 92.28-14%Add 187.71%19,213
IXJKen Fisher 2015-06-30 Add$107.16 - $112.88
($109.98)
$ 92.28-16%Add 9.14%6,678
IXJKen Fisher 2015-03-31 Reduce$98.86 - $110.66
($104.83)
$ 92.28-12%Reduce -13.27%6,119
IXJKen Fisher 2014-03-31 Buy $84.91 - $93
($89.14)
$ 92.284%New holding5,950
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

IXJ is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


IXJ: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Vanzeyst, Albert Wilhelmus10% Security Holder 2016-02-04Sell135,000$0.8610630.23view
Anwyll, Edward William DrewSenior Officer 2016-02-04Sell4,000$18.75392.16view
Galloway, JulieSenior Officer 2016-02-04Sell16,600$18.5398.81view
Higgs, Darcy Alan10% Security Holder 2016-02-04Sell18,025$0.422970view
Higgs, DennisDirector 2016-02-04Sell18,025$0.422970view
Taylor, Larry DouglasDirector 2016-02-04Buy36,000$0.192180view
Paquette, Raymon Lucien10% Security Holder, Director, Senior Officer 2016-02-04Buy5,000$0.1183790.91view
Hinchcliffe, Robert10% Security Holder, Director, Senior Officer 2016-02-04Buy30,000$0.192180view
Schellenberg, Gary David AlberDirector, Senior Officer 2016-02-04Buy20,000$0.06153700view
Schellenberg, Gary David AlberDirector, Senior Officer 2016-02-04Buy13,000$0.06153700view

Quarterly/Annual Reports about IXJ:

    News about IXJ:

    Articles On GuruFocus.com
    Yacktman Fund Comments on Staples Feb 05 2016 
    Yacktman Fund Comments on Apollo Feb 05 2016 
    Yacktman Fund Comments on C.H. Robinson Feb 05 2016 
    Yacktman Fund Comments on PepsiCo Feb 05 2016 
    Yacktman Fund Comments on P&G Feb 05 2016 
    Yacktman Fund Comments on Microsoft Feb 05 2016 
    Auxier Asset Management Year-End 2015 Market Commentary Feb 05 2016 
    On Running a Concentrated Portfolio Feb 05 2016 
    Mario Gabelli Comments on Rolls-Royce Holding plc Feb 05 2016 
    Mario Gabelli Comments on Legg Mason Inc. Feb 05 2016 

    More From Other Websites
    Novartis Reports Operational Growth in 4Q15 Feb 01 2016
    What Does Novartis Expect from Pharmaceuticals? Feb 01 2016
    Novartis’s 4Q15 Revenue Estimates: Expect a Fall! Jan 18 2016
    Novartis Will Report Its 4Q15 Earnings on January 27 Jan 18 2016
    What to Expect from GlaxoSmithKline’s 4Q15 Earnings Jan 13 2016
    Biotech On the Edge? Try Better-Performing Health Care ETFs Jan 12 2016
    The Top 5 Global Equity ETFs for 2016 (IXJ, VT) Jan 11 2016
    Thermo Fisher Scientific’s Latest Analyst Recommendations Jan 10 2016
    The Top 5 Health Care ETFs for 2016 (XLV, VHT) Jan 07 2016
    IXJ: iShares Global Healthcare ETF Dec 22 2015
    Overview of 2 Studies Supporting Alecensa’s Approval Dec 18 2015
    Alecensa Approved for ALK+ Non-Small Cell Lung Cancer Dec 18 2015
    Existing Treatments for Multiple Myeloma Dec 07 2015
    Aura Series: Studies Supporting Approval of Targisso Nov 17 2015
    AstraZeneca’s Tagrisso Approved by FDA for Lung Cancer Nov 17 2015
    Zacks Telescope (Sector/Industry/Company Ranks) Sep 08 2015
    Anatomy of '1,000 flash crashes': What went wrong Aug 24 2015
    The Bargain Stocks Leading The Next Trillion-Dollar Industry Jul 16 2015
    Behind the Stellar run for Healthcare ETFs Apr 10 2015
    Here’s Why I Like Healthcare Feb 20 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK